No abstract

Background: Fascioliasis is a worldwide parasitic infection caused by a food-borne trematode called Fasciola, and Fasciola infection has been reported in more than 80 countries. Recently, the WHO has presented a roadmap for overlooked diseases from 2021 to 2030, which aims to increase the prevention and control of overlooked different diseases such as Fascioliasis. Methods: Our main objective was to conduct a systematic review aiming to summarize recent knowledge on the Antiparasitic Compounds against Human Fascioliasis. A keyword search was performed in PubMed, Web of Science, to gather relevant literature published between the 17th of April 1992 and the 23rd October 2022. A total of 329 records were initially retrieved, with 28 full-text articles retained for the qualitative synthesis. Results: Up to now, various antiparasitic drugs have been used to treat human fascioliasis, the most important of which are: Triclabendazole, Albendazole and Bithionol, Praziquantel, Emetine and Dehydroemetine, Mebendazole in combination with Metronidazole and Nitazoxanide, Chloroquine, Hexylresorcinol. From the past to the present, natural herbal medicines have traditionally been used in most countries to treat various parasitic diseases in humans and animals so that these are known as active anthelmintic phytochemicals such as Artemisinin, Mirazid, Plumbagin, Lycium chinense. Conclusion: Although Triclabendazole is an effective and useful drug of choice for the treatment of human fascioliasis, but due to the gradual resistance of fasciolas to Triclabendazole, further research is needed to find new drugs. Despite many advances in antiparasitic compounds used against human fascioliasis, a number of integrated control measures should be implemented as strong management strategies for fascioliasis.

Introduction: Gp63 is the major surface glycoprotein of Leishmania which is prevalent in the promastigote stage of Phlebotomus sergenti. Glycoprotein 63 (gp63) or leishmanolysin is a zinc-dependent metalloprotease found on the surface of Leishmania. It was initially discovered in 1980and described biochemically and genetically as a surface antigen expressed in promastigotes of Leishmania species, having a range of substrates including casein, albumin, fibrinogen, haemoglobin, and gelatin. On the surface of amastigote, GP63 is present at a very low level. Glycoprotein 63 is a zinc-dependent metalloprotease that is active in the pH range of 7–10, which is neutral to alkaline. Materials and Methods: During the study, which was carried out in Al-Muthanna province from July 2017 to August 2018, about 2550 sand fly samples including 719 males and 1633 females were collected. Three species of sand flies were recorded according to morphological features which included Phlebotomus papatasi, Phlebotomus sergenti, and Sergentomyia sintoni. The caught specimens showed that P. papatasi was the most prevalent species. Two primers were used for the diagnosis of Leishmania spp. using a nested PCR technique, which was designed in a previous study for 1250 samples of sand flies from 25 locations in the study area. Results: Results showed that 13 samples were positive, containing DNA for the Leishmania parasite, and 12 samples were negative. Positive samples include 11 samples of L. major species and only 2 samples of L. tropica species. Additionally, the results showed that the L. major species was the dominant species in the study area. Positive samples (13) of sand flies had Leishmania parasite based on molecular diagnosis and virulence factor gene (Gp63) of Leishmania parasite was detected in sand flies using PCR method The results showed that virulence factor gene (Gp63) was detected on the surface of promastigote. This refers to the presence of Leishmania parasite in sand fly. The study is the first one which detected the presence of the virulence factors gene (GP63) of Leishmania in the body of sand flies. Conclusion: This study revealed the possibility of diagnosing leishmaniasis by virulence factor gene (Gp63) in leishmania promastigotes.